FAIL (the browser should render some flash content, not this).


Intelligent Bio-Systems

Applications

FAIL (the browser should render some flash content, not this).


Home
Unique Technology

For Both Research and Clinical Applications.
IBS's sequencing by synthesis technology is one of the few emerging technology with the capability to both cost effectively sequence entire complex genomes in large genome labs and a finite number of genes for clinical applications.


Read more about the IBS technology
Research Applications.
There are over 300,000 scientists worldwide pursuing DNA sequencing in academic, research and government institutions. Scientists use DNA sequencing to discover and analyze newScientist photo organisms, identify and determine the function of genes and non-coding regions of DNA and gain a better understanding of the causes for genetic disease. With the availability of IBS’s new technology, many RNA expression profiling and DNA mutation studies which are currently using more cost effective non-sequencing methods will be done using sequencing, as sequencing generates for more detailed and precise data.


DNA Resequencing and Clinical Requirements


Over the past 25 years, DNA sequencing has been dominated by researchers discovering organisms sequence for the first time (de novo). The market is now shifting where most sequencing being done is so called "resequencing" wherein the nominal sequence of an organism is know, and variations of that sequence are determined. Nearly all clinical and diagnostic applications are resequencing applications as well. For these types of applicaiotns, the importance shifrs from cost per base to acombination of failsafe precision, fast test time and low cost per test. Click here for a description of the technology.

Clinical Applications.
The IBS sequencing technology is uniquely able to addresst the requirements of the clinic.The instrument is about half the cost of any other high-throughput technology, the test time for producing high-quallity results is hours rather than days and the accuracy is extremely high

Cancer.
There are about 22 million cancer patients worldwide, including 4 million in the US, 10 million in Europe, 3 million in India and 2 million in China. The rate of incidence is expected to grow from 10 million per year to over 15 million per year over the next 20 years. The mutations in individuals’ genomes which can lead to cancer are so diverse, that many researchers believe that we will have to sequence a patient’s tumor DNA before we can effectively treat his disease.  The NCI has initiated the Cancer Genome Anatomy project to better understand the variations and expression characteristics of cancer cells. 

HIV/AIDS.
Modern AIDS is caused by the simultaneous infection of a number of HIV virus mutants, many of which are resistant to the common AIDS drugs. Sequencing based drug-resistance testing has become a standard of care, however, current sequencing technoolgy does not have the appropriate throughput to measure low population mutants.